[The development of biosimilars in oncology]

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Biological medicines are crucial in cancer treatment and supportive care.
• Patent expirations of original biologics have led to the development of biosimilars.
• Biosimilars are highly similar to reference biological products but not identical, with distinct development pathways from generics.

Purpose of the Study:

• To review advances in biosimilar development and application in clinical oncology.
• To highlight the challenges and opportunities associated with biosimilars in cancer care.
• To discuss the potential impact of biosimilars on healthcare costs and treatment strategies.

Main Methods:

• Review of current literature on biosimilar development and clinical oncology.
• Analysis of regulatory pathways for biosimilar approval.
• Examination of economic and clinical impact studies of biosimilars.

Main Results:

• Biosimilars, including rituximab, trastuzumab, and bevacizumab, are increasingly used in medical oncology.
• The development and evaluation of biosimilars differ significantly from small molecule generics.
• Biosimilars offer potential for significant healthcare cost reduction worldwide.
• These biological drugs can optimize clinical strategies and expand patient treatment options.

Conclusions:

• Biosimilars represent a significant advancement in oncology, offering comparable efficacy and safety to reference products.
• Their successful integration into clinical practice can lead to substantial healthcare savings.
• Further research and regulatory clarity are essential to maximize the benefits of biosimilars in cancer care.